Forte Biosciences, Inc. (NASDAQ: FBRX)

Forte Biosciences, Inc. is a clinical stage biopharmaceutical company focused on developing novel immunotherapies for autoimmune diseases. Its lead product candidate, FB102, is a proprietary anti CD122 monoclonal antibody designed to modulate interleukin 2 and interleukin 15 signaling pathways by blocking the CD122 subunit shared by IL2 and IL15 receptors. In preclinical studies, FB102 demonstrated potent inhibition of T cell and natural killer cell proliferation and activation while sparing regulatory T cell function. The antibody showed favorable pharmacokinetics and a clean safety profile in a Phase 1 healthy volunteer trial, with no dose limiting toxicities observed. Building on these results, Forte Biosciences initiated a Phase 1b trial in celiac disease in mid 2024 and a Phase 1b trial in non segmental vitiligo in early 2025, with additional exploration in alopecia areata and type 1 diabetes under investigation.

Forte Biosciences, Inc. does not currently generate revenue from product sales as its pipeline remains in preclinical and clinical stages. The company finances its operations through equity capital, having raised approximately $75.0 million in fiscal year 2025, $53.0 million in 2024, and $25.0 million in 2023 via private placements and public offerings. As of December 31, 2025, Forte Biosciences reported cash and cash equivalents of $77.0 million to support ongoing research and development activities. This liquidity is intended to fund the progression of FB102 through later stage clinical trials and associated manufacturing activities.

Within the competitive landscape of autoimmune therapeutics, Forte Biosciences, Inc. occupies an early stage niche with its differentiated FB102 antibody targeting the CD122 subunit of IL2 and IL15 receptors. Larger pharmaceutical companies such as Janssen, Pfizer, and Sanofi are pursuing treatments for celiac disease, vitiligo, and alopecia areata, while numerous biotech firms pursue similar immunomodulatory approaches. Forte Biosciences' competitive advantages stem from its proprietary mechanism of action, encouraging preclinical pharmacology data, and a growing patent portfolio that includes pending applications worldwide. The company's focus on indications with limited approved therapies, such as celiac disease patients unresponsive to a gluten free diet, further distinguishes its strategic position. Additionally, FB102's potential applicability to other immune mediated conditions like type 1 diabetes expands its addressable market beyond the current programs.

As a pre revenue biotech, Forte Biosciences, Inc. serves primarily clinical trial sites and patients enrolled in its studies for FB102. The company collaborates with contract research organizations to conduct Phase 1 and Phase 2 trials across multiple geographic locations in the United States. It also relies on contract manufacturing organizations for the production of FB102 drug substance and drug product under current good manufacturing practice standards. No specific customer names are disclosed in the filing.